Search

A research report from a Comprehensive Cancer Center in Saudi Arabia discusses outcomes of Secondary Central Nervous System Lymphoma (SCNSL) patients treated with carmustine/thiotepa conditioning and autologous stem cell transplant. The study included five patients with Diffuse Large B Cell Lymphoma and Burkitt's Lymphoma, showing promising results with 40% progression-free survival and overall survival rates at one year. The researchers concluded that aggressive salvage treatment with autologous stem cell transplant using carmustine/thiotepa conditioning could lead to long-term survival in some SCNSL patients, despite historically poor outcomes. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Xi'an Jiaotong University in China explored the efficacy and safety of a conditioning regimen for patients with non-Hodgkin lymphoma undergoing autologous hematopoietic stem cell transplantation. The study compared the BEA-PLM regimen with the traditional BEAM/BEAC regimen and found comparable outcomes in terms of relapse rates, progression-free survival, overall survival, and engraftment times. The BEA-PLM regimen showed a trend towards decreased relapse rates and improved survival, with manageable non-hematologic toxicities. This research provides valuable insights into potential treatment options for patients with non-Hodgkin lymphoma. [Extracted from the article]

A recent study from the University of Zabol in Iran explores the use of carmustine-loaded nanocarriers for targeted treatment of brain tumors in cancer therapy. The researchers aim to improve drug delivery to tumor sites while minimizing harmful effects on the body by encapsulating carmustine in nanocarriers. The study emphasizes the potential of carmustine nanocarriers in shaping the future of cancer treatment, highlighting the importance of advancements in this field. [Extracted from the article]

A clinical trial, NCT06687772, aims to prevent central nervous system (CNS) relapse in high-risk diffuse large B-cell lymphoma (DLBCL) patients through thiotepa-based autologous stem cell transplant. The study focuses on reducing the risk of CNS relapse in DLBCL patients by using thiotepa/carmustine conditioning during autologous stem cell transplantation. The trial is not yet recruiting participants and aims to enroll 36 patients, with a primary completion date of August 31, 2027. The study is conducted by Washington University School of Medicine and focuses on improving outcomes for DLBCL patients at high risk of secondary CNS recurrence. [Extracted from the article]

A clinical trial, NCT06692452, is being conducted to evaluate the effectiveness of tazemetostat in combination with CHOP chemotherapy for treating peripheral T-Cell Lymphoma (PTCL). The study involves the use of specific drugs like tazemetostat, cyclophosphamide, doxorubicin, vincristine, and prednisone. The trial aims to assess response rates, overall survival, progression-free survival, and treatment-related toxicities in participants. The study is expected to enroll 24 individuals and is supported by Ipsen. [Extracted from the article]

Researchers at Minia University in Egypt conducted a study on the adsorption behavior of anticancer drugs (Temozolomide, Carmustine, Procarbazine, and Lomustine) on zinc oxide nanocages using density functional theory. The study found that the nanocages efficiently adsorbed the drugs with negative binding energies, making them potential carriers for these drugs. The research concluded that zinc oxide nanocages are ideal for developing efficient anticancer drug carriers. Financial support for the study came from King Saud University. [Extracted from the article]

Researchers at Islamia University Bahawalpur conducted a study on using Borophene as a nanocarrier for the anti-cancer drugs carmustine and nitrosourea. The study found that carmustine is likely to be a promising nanocarrier for Borophene, while nitrosourea paired with Borophene shows potential as a biological carrier for drug delivery. The research focused on enhancing cancer treatment efficacy and addressing drug conflicts, with findings indicating the potential of Borophene as a drug delivery vehicle. The study was financially supported by King Saud University and has been peer-reviewed. [Extracted from the article]

A clinical trial, NCT06652139, is being conducted at Ruijin Hospital to evaluate the efficacy and safety of selinexor combined with BEAM as a preconditioning regimen for autologous stem cell transplantation in patients with relapsed and refractory diffuse large B-cell lymphoma with MYC positivity. The trial involves 82 patients who will be randomly assigned to receive either the experimental selinexor combined with BEAM regimen or the control BEAM regimen before undergoing ASCT therapy. The primary outcome measures include progression-free survival, overall survival, complete remission rate, time of hematopoietic reconstruction, and transplantation-related adverse reactions. [Extracted from the article]

Researchers from the University of Lodz in Poland have conducted a study on drug delivery systems (DDSs) for anticancer agents. They tested a recently synthesized molecule called TN as a potential drug carrier for the anticancer drug carmustine. The results showed that TN forms a stable complex with carmustine, reducing its toxicity to normal cells. This research provides valuable insights into the design and synthesis of drug carriers for more effective cancer therapies. [Extracted from the article]

A recent study conducted by researchers at Bangladesh University of Engineering and Technology explored the potential of a SiC nanosheet as a drug delivery system for anticancer drugs. Using density functional theory, the researchers investigated the interactions between the nanosheet and the drugs nitrosourea and carmustine. The study found that the adsorption process was energetically favorable and that the nanosheet showed high reactivity towards both drugs. Additionally, the researchers discovered that the nanosheet could be potentially used in phototherapy. This research provides valuable insights into the development of novel nanosheet-based drug delivery systems for cancer treatment. [Extracted from the article]

A recent report from the School of Life Sciences in Maharashtra, India, discusses the challenges of treating gliomas, a type of brain tumor. The report focuses on the use of the drug carmustine in glioma treatment and explores a new delivery system using flexible liposomes embedded in a nasal gel. The study found that this delivery system improved the targeted uptake of carmustine in the brain, making it a potentially effective treatment option for gliomas. Further research and development in this area could lead to advancements in cancer gene therapy. [Extracted from the article]

Ix Innovation LLC has been issued a patent for an apparatus, system, and method for implanting surgical material. The patent describes a system that uses a laser cutter network and imaging device to create a customized implant substrate for surgical procedures. The system captures an image of the patient's body, creates a two-dimensional profile based on the image, and shapes the implant substrate using a laser cutter. The system also includes the ability to add tabs to expand the size of the implant substrate and determine an accuracy score for the customized implant. This technology aims to provide a more precise and efficient method for implanting surgical material. [Extracted from the article]

A recent study conducted by the Yenepoya Research Centre in Karnataka, India, explores the challenges of delivering chemotherapeutic drugs to the brain to treat glioblastoma, a type of brain tumor. The researchers focused on formulating pH-responsive nanoliposomes loaded with carmustine, a drug that selectively targets malignant glioma cells due to their acidic pH. The study found that these liposomes effectively targeted the tumor cells and inhibited endothelial sprouting. This research provides valuable insights into potential alternative techniques for delivering drugs to the brain and improving the efficacy of cancer gene therapy. [Extracted from the article]

A recent study conducted in Maharashtra, India, explored the use of surface-modified, targeted nanocarriers in chemotherapy. The researchers focused on the efficacy of polydopamine-modified folic acid-conjugated liposomes loaded with carmustine for cancer therapy. The results showed that these liposomes had smaller particle size, good stability, and high cellular uptake compared to conventional liposomes. They also exhibited pH-sensitive properties and reduced harm to normal tissues. This research provides promising insights for future advancements in cancer treatment. [Extracted from the article]

A recent report from the University of Texas MD Anderson Cancer Center discusses research findings on multiple myeloma. The study focuses on the use of reduced-dose carmustine and melphalan as a conditioning regimen for multiple myeloma patients with central nervous system (CNS) involvement. The researchers found that this combination was safe and effective in penetrating the CNS, which is important for patients with CNS involvement. This study adds to the existing knowledge on conditioning chemotherapy prior to autologous stem cell transplantation in multiple myeloma patients. [Extracted from the article]

The surgical method as in claim 12, wherein the implant substrate is one or more of a drug implant substrate, prosthetic substrate, structural biologics substrate, or an antibiotic substrate. For example, the system may learn why the implant substrate receive the accuracy score and adjust the cutting profile based on the first implant substrate cut profile to cut a subsequent implant substrate. The instructions may further cause the processor to add one or more tabs to expand a size of the drug implant substrate and where creating the drug implant substrate may include cutting the drug implant substrate to include the one or more tabs. Creating the drug implant substrate may include shaping the drug implant substrate using the 2d laser cutter. [Extracted from the article]

For example, the system may learn why the implant substrate receive the accuracy score and adjust the cutting profile based on the first implant substrate cut profile to cut a subsequent implant substrate. The surgical method as in claim 12, wherein the implant substrate is one or more of a drug implant substrate, prosthetic substrate, structural biologics substrate, or an antibiotic substrate. Creating the drug implant substrate may include shaping the drug implant substrate using the 2d laser cutter. The instructions may further cause the processor to add one or more tabs to expand a size of the drug implant substrate and where creating the drug implant substrate may include cutting the drug implant substrate to include the one or more tabs. [Extracted from the article]

Arak, Iran, Alkylating Agents, Anticancer Agents, Antineoplastics, Cancer, Cancer Therapy, Carmustine Therapy, Drugs and Therapies, Emerging Technologies, Health and Medicine, Nanosheets, Nanotechnology, Nitrosourea Compounds, Oncology, Pharmaceuticals, Protective Agents, Carmustine Keywords: Arak; Iran; Alkylating Agents; Anticancer Agents; Antineoplastics; Cancer; Cancer Therapy; Carmustine; Carmustine Therapy; Drugs and Therapies; Emerging Technologies; Health and Medicine; Nanosheets; Nanotechnology; Nitrosourea Compounds; Oncology; Pharmaceuticals; Protective Agents EN Arak Iran Alkylating Agents Anticancer Agents Antineoplastics Cancer Cancer Therapy Carmustine Carmustine Therapy Drugs and Therapies Emerging Technologies Health and Medicine Nanosheets Nanotechnology Nitrosourea Compounds Oncology Pharmaceuticals Protective Agents 230 230 1 10/09/23 20231010 NES 231010 2023 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Nanotechnology - Nanosheets. The results reveal that the drug-loaded on a pure B3O3 sheet has reduced the band gap by about the 28-32%; thus, it can detect the drug well.". [Extracted from the article]

For more information on this research see: Impact of Thiotepa Dose-intensity In Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplant With Thiotepa/carmustine Conditioning. Keywords: Milwaukee; State:Wisconsin; United States; North and Central America; Antineoplastics; B-Cell Lymphoma; Cancer; Carmustine; Central Nervous System; Health and Medicine; Hematology; Hematopoietic; Immunoproliferative Disorders; Large B-Cell Lymphoma; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Nitrosourea Compounds; Oncology; Organothiophosphorus Compounds; Thiotepa Therapy EN Milwaukee State:Wisconsin United States North and Central America Antineoplastics B-Cell Lymphoma Cancer Carmustine Central Nervous System Health and Medicine Hematology Hematopoietic Immunoproliferative Disorders Large B-Cell Lymphoma Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Nitrosourea Compounds Oncology Organothiophosphorus Compounds Thiotepa Therapy 359 359 1 09/11/23 20230912 NES 230912 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Fresh data on Oncology - B-Cell Lymphoma are presented in a new report. [Extracted from the article]

Keywords: Maharashtra; India; Asia; Alkylating Agents; Antineoplastics; Biotechnology; Cancer; Cancer Gene Therapy; Carmustine; Carmustine Therapy; Drugs and Therapies; Gene Therapy; Health and Medicine; Nitrosourea Compounds; Oncology; Pharmaceuticals EN Maharashtra India Asia Alkylating Agents Antineoplastics Biotechnology Cancer Cancer Gene Therapy Carmustine Carmustine Therapy Drugs and Therapies Gene Therapy Health and Medicine Nitrosourea Compounds Oncology Pharmaceuticals 7 7 1 08/14/23 20230814 NES 230814 2023 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology - Cancer Gene Therapy have been published. Maharashtra, India, Asia, Alkylating Agents, Antineoplastics, Biotechnology, Cancer, Cancer Gene Therapy, Carmustine, Drugs and Therapies, Gene Therapy, Health and Medicine, Nitrosourea Compounds, Carmustine Therapy, Oncology, Pharmaceuticals. [Extracted from the article]

Keywords: Alkylating Agents; Antimetabolites; Antineoplastics; Biomedicine; Bone Marrow Cells; Cancer; Carmustine; Carmustine Therapy; Cell Transplantation; Cell Transplants; Clinical Research; Clinical Trials and Studies; Cytarabine Therapy; Drugs and Therapies; Etoposide; Etoposide Therapy; Health and Medicine; Hematology; Hematopoietic; Hematopoietic Stem Cells; Hospitals; Immunoproliferative Disorders; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Melphalan Therapy; Mitotic Inhibitors; Naphthalenes; Nitrosourea Compounds; Oncology; Pharmaceuticals; Podophyllotoxin; Stem Cell Research; Surgery; Transplant Medicine; Transplant Medicine - Cell Transplants EN Alkylating Agents Antimetabolites Antineoplastics Biomedicine Bone Marrow Cells Cancer Carmustine Carmustine Therapy Cell Transplantation Cell Transplants Clinical Research Clinical Trials and Studies Cytarabine Therapy Drugs and Therapies Etoposide Etoposide Therapy Health and Medicine Hematology Hematopoietic Hematopoietic Stem Cells Hospitals Immunoproliferative Disorders Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Melphalan Therapy Mitotic Inhibitors Naphthalenes Nitrosourea Compounds Oncology Pharmaceuticals Podophyllotoxin Stem Cell Research Surgery Transplant Medicine Transplant Medicine - Cell Transplants 189 189 1 07/17/23 20230720 NES 230720 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Staff editors report on the newly launched clinical trial, NCT05931263, which has the following summary description: "The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. [Extracted from the article]

Alkylating Agents, Antimetabolites, Antineoplastics, Bendamustine Therapy, Biomedicine, Cancer, Carmustine, Carmustine Therapy, Cell Transplantation, Cell Transplants, Cytarabine Therapy, Drugs and Therapies, Etoposide, Etoposide Therapy, Health and Medicine, Hematology, Immunoproliferative Disorders, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Melphalan Therapy, Mitotic Inhibitors, Naphthalenes, Nitrosourea Compounds, Oncology, Pharmaceuticals, Surgery, Transplant Medicine, Podophyllotoxin Keywords for this news article include: Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China, Asia, Antimetabolites, Antineoplastics, Biomedicine, Pharmaceuticals, Cancer, Surgery, Lymphoma, Oncology, Hematology, Naphthalenes, Podophyllotoxin, Alkylating Agents, Etoposide Therapy, Melphalan Therapy, Carmustine Therapy, Cytarabine Therapy, Mitotic Inhibitors, Drugs and Therapies, Health and Medicine, Transplant Medicine. [Extracted from the article]

Keywords: Shanghai; People's Republic of China; Asia; Alcohols; Alkylating Agents; Antineoplastics; Cancer; Carmustine; Carmustine Therapy; Cellular Structures; Drugs and Therapies; Emerging Technologies; Extracellular Matrix; Extracellular Space; Glioblastomas; Health and Medicine; Hydrogel; Nanoparticles; Nanotechnology; Nitrosourea Compounds; Oncology; Organic Chemicals; Pharmaceuticals; Polyethylene Glycols EN Shanghai People's Republic of China Asia Alcohols Alkylating Agents Antineoplastics Cancer Carmustine Carmustine Therapy Cellular Structures Drugs and Therapies Emerging Technologies Extracellular Matrix Extracellular Space Glioblastomas Health and Medicine Hydrogel Nanoparticles Nanotechnology Nitrosourea Compounds Oncology Organic Chemicals Pharmaceuticals Polyethylene Glycols 246 246 1 04/17/23 20230418 NES 230418 2023 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Researchers detail new data in Oncology - Glioblastomas. Free drugs were released instantly to kill the residual tumor cells, while drugs in nanoparticles were continuously released to achieve a continuous and effective inhibition of the residual tumor cells for 30 days. [Extracted from the article]

Keywords: Tehran; Iran; Alkylating Agents; Antimetabolites; Antineoplastics; Carmustine; Carmustine Therapy; Drugs and Therapies; Emerging Technologies; Health and Medicine; Hydroxyurea; Hydroxyurea Therapy; Nanosheets; Nanotechnology; Nitrosourea Compounds; Pharmaceuticals; Urea EN Tehran Iran Alkylating Agents Antimetabolites Antineoplastics Carmustine Carmustine Therapy Drugs and Therapies Emerging Technologies Health and Medicine Hydroxyurea Hydroxyurea Therapy Nanosheets Nanotechnology Nitrosourea Compounds Pharmaceuticals Urea 1093 1093 1 03/24/23 20230228 NES 230228 2023 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Nanotechnology - Nanosheets. Thus, HU/f-CN and BCN/f-CN complexes are favorable systems and functionalized nanosheet is a better carrier in comparison to pristine nanosheet for the HU and BCN drug delivery system.". [Extracted from the article]